Redeye comments on Camurus' Q1 report 2026, which was below our estimates due to lower revenues from Buvidal and Brixadi. The Buvidal miss can largely be explained by a tough UK market and the reorganisation there. However, the underlying operations continue to grow and an increasing number of patients are on treatment. We make limited changes to our base case.
LÄS MER
